SCTX
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Scribe Therapeutics with a Buy and maintains $60 price target. ...
- GlobeNewswire
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering ...
- GlobeNewswire
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies ...
- Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Scribe Therapeutics with a Buy rating and announces Price Target of $60. ...
- Analyst Upgrades
Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60
Wells Fargo analyst Yanan Zhu initiates coverage on Scribe Therapeutics with a Overweight rating and announces Price Target of $60. ...
- Analyst Upgrades
Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37
Leerink Partners analyst David Risinger initiates coverage on Scribe Therapeutics with a Outperform rating and announces Price Target of $37. ...
- Analyst Upgrades
Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics with a Buy rating and announces Price Target of $50. ...
- GlobeNewswire
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies ...
- GlobeNewswire
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies ...